RxDoctor Payments Data

Gaurav Kapur, MD

Pediatric Nephrology · Detroit, MINPI 1093994576

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,750 of the $2,888 with a category attached, or 60.6%. Every reported general payment came from a single manufacturer, AstraZeneca.

$2,888in general payments, 2019–2025

Across 7 payments — averaging $412.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
$121,964in research payments, 2019–2025

Across 98 payments — averaging $1244.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$87K
  • AMAG Pharmaceuticals, Inc.$35K

What the payments were for

  • Consulting fees$1,75061%
  • Speaking & faculty fees$1505%
  • Travel & lodging$75526%
  • Food & beverage$2338%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$2,888

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,888 in reported general payments places this provider in the 85th percentile of 28 pediatric nephrology providers in Michigan.

See all pediatric nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$165,781
Medicare patients
20
Services billed
1,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$42

Paid to pharmacies, not to this prescriber.

Other pediatric nephrology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →